expressTEC develops RNA and AI-based technology to accurately select patients for targeted cancer therapies. Their initial product, expressPIK, is an in-vitro companion diagnostic test for PIQRAY® treatment eligibility, identifying common breast tumor mutations. This platform aims to improve therapeutic efficacy, increase patient response rates, and minimize adverse side effects across various cancer types.
Funding
$110K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Breast cancer patients are often misdiagnosed, leading to ineffective treatments and unnecessary side effects due to the limitations of traditional DNA testing in determining eligibility for targeted therapies. This misguidance results in lower treatment response rates and a diminished quality of life for patients.
Solution
expressTEC is developing expressPIK, an RNA and AI-based in-vitro diagnostic test designed to improve the selection of breast cancer patients for targeted therapies. By analyzing tumor RNA for specific mutations, expressPIK aims to provide a more accurate assessment of treatment eligibility compared to traditional DNA-based methods. The expressPIK platform is designed to identify the most common mutations found in breast tumors, serving as a proof of concept for a broader platform capable of testing for multiple mutations across various cancer types. The goal is to minimize the number of patients undergoing ineffective treatments, reduce side effects, and improve overall survival rates.
Target Audience
The primary target audience includes healthcare professionals, hospitals, and clinical labs involved in breast cancer treatment and seeking to improve patient outcomes through personalized therapy selection.
Features
- RNA-based in-vitro diagnostic test for PIQRAY® treatment eligibility
- AI-driven analysis of tumor RNA to identify targetable mutations
- Designed to improve treatment response rates compared to DNA testing
- Aims to minimize side effects associated with ineffective treatments
- Scalable platform for testing multiple mutations in various cancer types (future development)
- Provides quantitative biomarkers and a prognostic AI algorithm